You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Exact Sciences discussed newly released data and its plans for Cologuard, while Luminex provided details about its warning letter from the FDA.
The firm plans to begin its OTC efforts with a COVID antigen test but also sees potential in migrating other infectious disease tests.
Qiagen discussed what's in store after a failed bid by Thermo Fisher Scientific, and COVID-19 remained a hot topic on the second day of the virtual conference.
Last year, the company processed more than 1 million tests, most of them for its reproductive health business, but interest in Prospera and Signatera is growing.
Hologic said the acquisition of Biotheranostics will give it a company that operates in markets that are adjacent and complementary to its own.
Among firms presenting on the first day, Roche provided insights into its COVID-19 testing business, and Guardant said it plans to launch a comprehensive tissue sequencing assay.
The firm also provided preliminary revenues of $950 million for Q4 and reinstated guidance of $3.79 billion to $3.88 billion for 2021.
The company anticipates total revenues of $3.9 billion for 2020, including $1 billion from its COVID-19-related business.
The diagnostic firms were the final companies in the coverage universe of 360Dx to present at the annual conference.
Natera discussed its cancer and transplant rejection testing businesses, while Exact Sciences explained how it will benefit from its Genomic Health acquisition.